ストックスクリーナーアプリを入手
1.31
9.66%
-0.14
アフターアワーズ：
1.34
0.03
+2.29%
Proqr Therapeutics N V (PRQR) 最新ニュース
ProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
FY2028 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Press Releases about ProQR Therapeutics N.V.Ordinary Shares (Nasdaq:PRQR) - FinancialContent
ProQR Therapeutics N.V.Ordinary Shares (PRQR) Stock Price, News, Quote & History - financialcontent.com
HC Wainwright Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - MarketBeat
Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media
ProQR Therapeutics N.V.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Nigeria
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com South Africa
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com India
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com UK
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com
ProQR doses first participant in AX-0811 phase 1 trial - investing.com
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com Canada
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com India
A liver disease trial has dosed its first volunteer. ProQR expects early study data in January 2027. - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR to Participate in Upcoming Investor Conferences in September 2026 - The Manila Times
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - marketbeat.com
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com Canada
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com UK
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - siam.in
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
4.22%
大文字化:
|
ボリューム (24 時間):